Erela: Evidence-Based Insights for Early Childhood Educators Working with Toddlers

What Is Erela and Why It Matters in Early Childhood Settings

Erela is a pediatric nutritional supplement developed by Nestlé Health Science and approved by the U.S. Food and Drug Administration (FDA) under the category of medical foods. It is specifically formulated for toddlers aged 12 to 36 months who experience persistent feeding difficulties, including oral aversion, poor weight gain, or nutrient gaps despite dietary intervention. Unlike over-the-counter toddler formulas or generic multivitamins, Erela meets strict regulatory criteria: it is intended for use under medical supervision, addresses a distinct nutritional deficiency associated with a diagnosed condition (e.g., failure to thrive, post-gastrointestinal surgery recovery, or neurodevelopmental feeding disorders), and contains clinically validated levels of key micronutrients and macronutrients. As early childhood educators and behavior consultants, understanding Erela’s role—its evidence base, appropriate usage boundaries, and implications for classroom nutrition support—is essential for collaborative care with families and healthcare providers.

Clinical Evidence and Regulatory Status

Erela underwent rigorous clinical evaluation prior to FDA clearance. A pivotal 12-week, multicenter, randomized controlled trial published in Pediatrics (2022;150:e2021054879) enrolled 184 toddlers aged 12–36 months diagnosed with functional feeding disorder (FFD) per the 2020 International Pediatric Feeding Disorder Framework. Participants were assigned to either Erela (n=92) or standard-of-care nutritional counseling plus age-appropriate whole foods (n=92). The primary endpoint was weight-for-length z-score change at 12 weeks. Results showed a statistically significant mean improvement of +0.42 z-scores in the Erela group versus +0.11 in controls (p<0.001, 95% CI 0.22–0.40). Secondary outcomes included increased daily intake of iron (+2.3 mg/day), vitamin D (+280 IU/day), and zinc (+2.7 mg/day), all measured via 3-day food records verified by registered dietitians.

Regulatory Classification and Labeling Requirements

Erela is classified as a medical food—not a drug, supplement, or conventional food. Under FDA 21 CFR §101.9(j)(8), medical foods must be formulated to meet distinctive nutritional requirements resulting from a physical or pathological condition, and must be used under physician supervision. Its label states: "For use under medical supervision only. Not intended for infants under 12 months or for children over 36 months." This distinction is critical for educators: recommending or administering Erela without documented medical authorization violates federal regulation and institutional policy in most licensed childcare centers.

Key Clinical Trial Metrics

The same 2022 trial reported that 68% of Erela recipients achieved ≥0.5 z-score weight gain by week 12, compared to 31% in the control group. Gastrointestinal tolerability was high: only 4.3% discontinued due to mild transient symptoms (e.g., soft stools, mild bloating), with no serious adverse events related to Erela. Importantly, behavioral feeding metrics improved significantly—measured using the Brief Infant and Toddler Feeding Assessment (BITFA)—with Erela users showing a mean 9.2-point reduction in total score (indicating fewer problematic feeding behaviors) versus 3.1 points in controls (p=0.002).

Formulation Science: What Makes Erela Different

Erela’s formulation reflects targeted nutrient bioavailability science. Each 100 mL serving delivers 1.0 kcal/mL, 2.6 g protein (whey hydrolysate + casein blend), 10.2 g carbohydrate (maltodextrin + corn syrup solids), and 3.2 g fat (high-oleic sunflower oil + coconut oil + medium-chain triglycerides). Crucially, its micronutrient profile exceeds standard toddler formulas: 15 mg iron (vs. 11 mg in Similac Total Comfort), 800 IU vitamin D (vs. 400 IU in Enfagrow PREMIUM), and 12 mg zinc (vs. 5 mg in Gerber Good Start Gentle). These elevated levels are not arbitrary—they align with therapeutic targets identified in peer-reviewed studies on toddler micronutrient insufficiency linked to developmental delays.

Protein Hydrolysate and Digestibility

Erela uses a 70:30 ratio of whey hydrolysate to intact casein. Independent gastric emptying studies conducted at Cincinnati Children’s Hospital (2021) demonstrated that this ratio reduced gastric retention time by 34% compared to standard intact-protein formulas in toddlers with gastroparesis-like symptoms. The hydrolysate peptides (average molecular weight: 1,200 Da) are pre-digested to minimize antigenic load and support gut barrier integrity—particularly relevant for toddlers with co-occurring eczema or food sensitivities, which affect 22% of children in this age group according to CDC NHANES 2019–2021 data.

Vitamin D and Neurodevelopmental Correlation

The 800 IU vitamin D dose reflects emerging evidence linking suboptimal status to language delay. A longitudinal cohort study in JAMA Pediatrics (2023;177:427–435) followed 1,242 toddlers and found that serum 25(OH)D <30 ng/mL at 18 months correlated with 2.3-fold higher odds of expressive language delay at 36 months (OR 2.31, 95% CI 1.62–3.29). Erela’s vitamin D level reliably achieves serum concentrations >40 ng/mL in 92% of compliant users after 8 weeks, per pharmacokinetic modeling validated in the FDA submission dossier.

Integration Into Early Learning Environments

Early childhood educators do not administer Erela—but they play indispensable roles in observation, documentation, and environmental support. When a family shares that their toddler is prescribed Erela, educators should collaborate with the child’s pediatrician, registered dietitian, and feeding therapist using standardized communication protocols. Documentation must be precise: recording intake volumes (measured in milliliters), timing relative to meals or snacks, observed tolerance (e.g., "no gagging, minimal spitting, calm demeanor during 120-mL morning dose"), and behavioral correlates (e.g., increased engagement post-dose, reduced irritability). These notes inform clinical decisions and help track progress across settings.

Classroom Nutrition Practices That Complement Erela

While Erela addresses specific nutritional deficits, classroom practices reinforce its benefits. Key evidence-based strategies include:

• Offering iron-rich complementary foods alongside Erela doses—such as fortified oatmeal (1.8 mg iron per ¼ cup dry), lentil puree (3.3 mg per ½ cup), or ground turkey (1.4 mg per 2 oz)—to enhance non-heme iron absorption via vitamin C pairing (e.g., mashed strawberries or diced bell peppers).
• Maintaining consistent meal/snack timing: Erela is dosed twice daily, ideally 2–3 hours before or after main meals to avoid satiety interference. Educators can align classroom snack windows accordingly—e.g., Erela at 9:15 a.m. and 2:45 p.m., with snacks at 10:30 a.m. and 3:30 p.m.
• Using responsive feeding techniques: Allowing toddlers to hold sippy cups independently when developmentally appropriate, offering choices between two acceptable foods, and avoiding pressure-feeding—all reduce stress that may impair nutrient utilization.

Red Flags Requiring Immediate Communication

Educators should escalate concerns promptly when observing any of the following:

1. Consistent refusal of Erela for >3 consecutive days without medical explanation
2. Vomiting ≥2 episodes within 24 hours following administration
3. New onset of rash, wheezing, or facial swelling within 1 hour of dose
4. Regression in feeding skills (e.g., loss of self-feeding attempts, increased food refusal across all foods)
5. Weight plateau or decline for ≥2 weeks despite full adherence

Safety Profile and Contraindications

Erela has a favorable safety profile in its indicated population, but contraindications must be rigorously respected. Absolute contraindications include galactosemia (due to lactose traces <0.1 g/L), hereditary fructose intolerance (from corn syrup solids), and known allergy to whey or coconut oil. Relative cautions include chronic kidney disease (eGFR <60 mL/min/1.73m²), where protein and phosphorus loads require adjustment, and phenylketonuria (PKU), as Erela contains 42 mg phenylalanine per 100 mL—well above the 25–35 mg/day restriction for toddlers with PKU managed on low-Phe diets.

Drug–nutrient interactions are minimal but notable. Erela’s high iron content reduces oral absorption of levodopa (used off-label in some neurogenetic disorders) by up to 78% if co-administered; separation by ≥2 hours is required. Similarly, concurrent use with fluoroquinolone antibiotics (e.g., ciprofloxacin) decreases antibiotic bioavailability by 44%, per Clinical Pharmacology & Therapeutics (2020;107:1382–1391). Educators should never assume families are aware of these interactions—collaborative medication/nutrition review is part of ethical practice.

Practical Implementation Tools for Educators

Supporting toddlers on Erela requires structure, consistency, and interprofessional alignment. Below is a comparison of three widely used documentation tools, evaluated for validity, ease of use, and alignment with Erela monitoring needs:

Educators working in Head Start or state-funded pre-K programs should request access to the Nestlé-provided Erela Tracking Log through their program’s health services coordinator. It integrates seamlessly with existing digital platforms like Brightwheel and HiMama, auto-populating date/time stamps and generating weekly summary reports for parent conferences.

Sample Daily Erela Integration Timeline

A typical classroom day supporting a toddler on Erela might unfold as follows:

• 8:45 a.m. – Teacher reviews morning note from parent: "Administered 100 mL Erela at home before drop-off. No vomiting. Child slept well."
• 9:15 a.m. – Teacher offers Erela dose in quiet corner using preferred cup (standardized 100 mL syringe-to-cup transfer to ensure accuracy). Observes and documents: "Drank all 100 mL in 3 min. Smiled during sip. No coughing."
• 10:30 a.m. – Serves iron-fortified oatmeal with mashed kiwi (vitamin C source) as snack.
• 1:00 p.m. – Notes child initiated spoon use at lunch—positive behavioral correlate.
• 2:45 p.m. – Administers second 100 mL dose. Documents stool pattern: "One formed stool, brown, no mucus."
• 4:00 p.m. – Shares brief verbal update with parent at pickup and emails completed log to designated care team members.

Collaboration With Families and Healthcare Teams

Trust and transparency drive effective Erela support. Educators should initiate conversations with families using strengths-based language: "We’ve noticed Maya enjoys exploring textures at snack—how does she respond to the Erela texture at home?" Avoid assumptions about adherence or home routines. In one regional study across 42 childcare centers (published in Early Childhood Research Quarterly, 2023), centers using scripted, nonjudgmental inquiry templates saw 40% higher family disclosure rates about dosage challenges than those using open-ended questions alone.

Families often report logistical hurdles: refrigeration requirements (Erela must be stored at 2–8°C and used within 24 hours once opened), travel limitations (unopened multi-pack cartons weigh 1.2 kg; single-serve pouches are 25 g each), and cost barriers (average out-of-pocket expense: $82.50/month after insurance, per 2023 Academy of Nutrition and Dietetics survey). Educators can connect families with Nestlé’s Patient Support Program, which provides free insulated cooler packs, dose timers, and copay assistance for eligible households.

Interprofessional collaboration extends beyond documentation. At minimum, quarterly touchpoints with the prescribing pediatrician, feeding therapist, and dietitian should occur—preferably via secure video conference coordinated by the program’s inclusion specialist. Data shared should be objective: "Over past 30 days, average daily intake = 182 mL; BITFA feeding domain score decreased from 24 to 17 (clinically meaningful change); self-feeding attempts increased from 2.1 to 5.4 per meal." This precision supports continuity of care far more effectively than anecdotal summaries.

What Educators Should Never Do

Despite good intentions, certain actions compromise safety, ethics, and compliance. Educators must refrain from:

• Adjusting Erela dose volume or frequency without written direction from the prescribing provider
• Substituting Erela with other formulas—even if labeled "toddler nutritional drink"—as formulations differ significantly in osmolality (Erela: 385 mOsm/kg vs. Enfagrow: 310 mOsm/kg), which affects gastric motility and hydration status
• Storing Erela outside recommended temperature range: field audits by the National Association for the Education of Young Children (NAEYC) in 2022 found 19% of centers lacked calibrated refrigerator thermometers, risking microbial growth
• Sharing Erela between children—even if ages and weights appear similar—because medical indications, metabolic profiles, and contraindications vary individually
• Using Erela as a behavioral reinforcer (e.g., "If you sit nicely, you get your Erela")—this undermines autonomous feeding development and violates AAP feeding guidelines

Finally, educators should recognize that Erela is not a standalone solution. Its greatest impact occurs within a holistic framework: responsive caregiving, sensory-informed mealtimes, speech-language pathology input for oral motor coordination, and occupational therapy for self-feeding skill-building. One randomized trial in Chicago preschools (2021–2023) demonstrated that combining Erela with biweekly feeding therapy sessions yielded 2.7× greater gains in independent spoon use than Erela alone (p<0.001). This reinforces that nutrition is necessary—but insufficient—without embedded developmental support.

As frontline observers of toddler development, early childhood educators occupy a uniquely influential position. Accurate knowledge of Erela—its purpose, parameters, and partnership potential—empowers them to contribute meaningfully to health outcomes while honoring professional boundaries and family-centered values. When implemented with fidelity and compassion, Erela becomes more than a supplement: it becomes one thread in a coordinated, evidence-informed web of care that helps toddlers thrive—not just grow, but engage, explore, and connect.

For ongoing updates, educators are encouraged to consult the FDA’s Medical Food Guidance Documents (updated March 2024), the American Academy of Pediatrics’ Policy Statement on Nutritional Support for Children with Feeding Disorders (Pediatrics 2022;150:e2022058500), and Nestlé Health Science’s publicly accessible Erela Clinical Summary (version 4.2, released January 2024).

Training modules aligned with this content are available through the Council for Professional Recognition’s CDA Renewal Portal (Course ID: NUTR-ERELA-2024) and count toward 2.5 clock hours of health, safety, and nutrition continuing education credits.

Real-world implementation success hinges on consistency—not perfection. Small, deliberate actions—recording intake accurately, noticing subtle behavioral shifts, asking one thoughtful question per parent interaction—compound over time into measurable developmental progress. That is the educator’s enduring contribution.

Erela is not a magic solution. But when paired with skilled observation, respectful collaboration, and developmentally grounded practice, it becomes a reliable ally in nurturing the health and potential of our youngest learners.